Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Pulmonx Co. (NASDAQ:LUNG) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $14.83.

Several equities analysts recently issued reports on LUNG shares. Lake Street Capital began coverage on shares of Pulmonx in a research report on Tuesday, June 4th. They set a “buy” rating and a $12.00 price target on the stock. Wells Fargo & Company reduced their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Finally, Canaccord Genuity Group raised their target price on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st.

Insider Transactions at Pulmonx

In other Pulmonx news, General Counsel David Aaron Lehman sold 5,765 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total value of $38,567.85. Following the sale, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares in the company, valued at approximately $1,979,401.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel David Aaron Lehman sold 5,765 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total value of $38,567.85. Following the sale, the general counsel now owns 203,348 shares in the company, valued at $1,360,398.12. The disclosure for this sale can be found here. Insiders have sold a total of 11,535 shares of company stock valued at $76,587 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in Pulmonx in the 2nd quarter worth about $37,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Pulmonx by 609.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after purchasing an additional 7,316 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Pulmonx during the second quarter valued at approximately $93,000. Quest Partners LLC bought a new position in Pulmonx during the fourth quarter valued at approximately $94,000. Finally, EntryPoint Capital LLC purchased a new stake in Pulmonx in the first quarter worth approximately $102,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Price Performance

Shares of LUNG stock opened at $8.31 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. The firm has a market cap of $322.56 million, a P/E ratio of -5.40 and a beta of 0.63. The business’s 50 day moving average price is $7.07 and its 200-day moving average price is $7.63. Pulmonx has a fifty-two week low of $5.46 and a fifty-two week high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The business had revenue of $20.78 million for the quarter, compared to analysts’ expectations of $20.23 million. On average, equities research analysts anticipate that Pulmonx will post -1.64 earnings per share for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.